A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies

Blood

Volumn 100, Issue 5, 2002, Pages 1525-1531

  Couban, Stephen ^{a,b,c,d,e,f,g,h,i,j,k}   Simpson, David R ^{a,b,c,d,e,f,g,h,i,j}   Barnett, Michael J ^{a,b,c,d,e,f,g,h,i,j}   Bredeson, Christopher ^{a,b,c,d,e,f,g,h,i,j}   Hubesch, Lothar ^{a,b,c,d,e,f,g,h,i,j}   Howson Jan, Kang ^{a,b,c,d,e,f,g,h,i,j}   Shore, Tsiporah B ^{a,b,c,d,e,f,g,h,i,j}   Walker, Irwin R ^{a,b,c,d,e,f,g,h,i,j}   Browett, Peter ^{a,b,c,d,e,f,g,h,i,j}   Messner, Hans A ^{a,b,c,d,e,f,g,h,i,j}   Panzarella, Tony ^{a,b,c,d,e,f,g,h,i,j}   Lipton, Jeffrey H ^{a,b,c,d,e,f,g,h,i,j}  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NORTH SHORE HOSPITAL   (New Zealand)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ THE UNIVERSITY OF AUCKLAND   (New Zealand)

^j UNIVERSITY OF TORONTO   (Canada)

^k QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; HLA ANTIGEN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYELODYSPLASIA; NEUTROPHIL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SIBLING; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036720739     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0048     Document Type: Article

References (43)

1. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
2. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants
3. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation
4. Choosing the source of stem cells for allogeneic transplantation: No longer a peripheral issue
5. Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: Timing of harvesting and composition of the leukapheresis product
6. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia
7. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
8. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
9. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
10. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
11. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor
12. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation
13. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells
14. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor
15. High incidence of chronic GVHD after primary allogenelc peripheral blood stem cell transplantation in patients with hematologic malignancies
16. Long-term follow-up of high-risk allogenelc peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality
17. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies
18. Allogeneic peripheral blood progenitor cell transplantation: Analysis of short-term engraftment and acute GVHD incidence in 33 cases
19. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
20. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
21. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
22. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD
23. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation
24. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
25. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle
26. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial
27. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation
28. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
29. Regimen-related toxicity in patients undergoing bone marrow transplantation
30. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial
31. The ISHAGE guidelines for CD34+ cell determination by flow cytometry
32. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification
33. A prospec-live, randomized trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies
34. Group sequential methods in the design and analysis of clinical trials
35. 1994 Consensus Conference on Acute GVHD Grading
36. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
37. Nonparametric estimation from incomplete observations
38. Regression models and lifetables
39. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
40. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease; impact on blood progenitor cell transplantation
41. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation